{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.96","value":"-0.3"},{"groupId":"OG001","spread":"16.71","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.17","value":"2.0"},{"groupId":"OG001","spread":"15.95","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG001","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEAN","populationDescription":"ITT Analysis Set; Only participants with data at both baseline and each post-baseline visit were included in the calculation of change from baseline.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12, and Week 24","title":"Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}